Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. develops antibody-based medicines for autoimmune and rare diseases, with a central focus on thyroid eye disease. Its TED portfolio includes veligrotug, an intravenously administered humanized monoclonal antibody targeting IGF-1R, and elegrobart, a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R.
Recurring company news covers clinical results from the THRIVE and REVEAL programs, regulatory updates for biologics applications, commercial preparation for TED therapies, and progress across earlier pipeline work, including anti-TSHR and FcRn inhibitor programs. Viridian also reports financial results, public equity and convertible-note financings, royalty-related funding updates, and Nasdaq inducement equity grants tied to employee compensation.
Viridian Therapeutics (NASDAQ: VRDN) announced that the FDA accepted the Biologics License Application for veligrotug to treat thyroid eye disease and granted Priority Review with a PDUFA target action date of June 30, 2026. Priority Review shortens the review timeline to six months. Veligrotug already holds Breakthrough Therapy designation. The BLA is supported by positive topline data from two global phase 3 trials (THRIVE and THRIVE-2) that met primary and all secondary endpoints, including the first phase 3 demonstration of statistically significant diplopia response and resolution in chronic TED and a rapid proptosis response. Veligrotug is a five-infusion IV course completed in 12 weeks. Viridian plans an EMA Marketing Authorization Application submission in Q1 2026.
Viridian Therapeutics (Nasdaq: VRDN) announced that its Compensation Committee approved non-qualified stock options totaling 171,900 shares as inducement grants to three new employees on Dec 1, 2025 under Nasdaq Listing Rule 5635(c)(4).
The options were granted outside the company’s 2016 Equity Incentive Plan but remain subject to its terms, have an exercise price equal to the Dec 1, 2025 closing price, and vest over four years (25% after one year, then monthly over 36 months) subject to continued employment.
The release also summarizes Viridian’s clinical programs, noting that veligrotug (VRDN-001) reported positive topline results in two global Phase 3 trials (THRIVE and THRIVE-2) and that VRDN-003 is in two ongoing global Phase 3 pivotal trials (REVEAL-1 and REVEAL-2).
Viridian Therapeutics (Nasdaq: VRDN) announced that on November 3, 2025 its Compensation Committee approved inducement grants of non-qualified stock options to purchase an aggregate of 88,300 shares for four new employees. The grants were made outside the company’s equity plan pursuant to Nasdaq Listing Rule 5635(c)(4) and remain subject to the plan’s terms.
The options have an exercise price equal to the closing price on the Grant Date and vest over four years: 25% at one year, then monthly vesting for 36 months, subject to continued employment.
Company background: Viridian is advancing veligrotug (two completed global Phase 3 trials, THRIVE and THRIVE-2, with positive topline results) and VRDN-003 (ongoing REVEAL-1 and REVEAL-2 Phase 3 trials), plus FcRn inhibitor programs VRDN-006 and VRDN-008.
Viridian Therapeutics (NASDAQ: VRDN) reported Q3 2025 results and progress including an October 2025 BLA submission for veligrotug to the FDA with a Priority Review request and a potential U.S. launch in mid-2026 if approved. The company completed a comprehensive financing package in October providing up to $889 million of potential capital, including a $289.1 million equity offering, a royalty financing with DRI (up to $300 million, including $55 million upfront and $115 million near-term milestones) and an amended Hercules credit facility (up to $300 million).
Cash was approximately $887.9 million as of October 31, 2025. VRDN-003 pivotal trials (REVEAL-1/REVEAL-2) completed enrollment and topline readouts are expected in Q1 2026 and Q2 2026. VRDN-006 showed phase 1 IgG reduction proof-of-concept; VRDN-008 IND remains on track with healthy volunteer data expected in 2H 2026. Q3 R&D was $86.3M and G&A $24.3M.
Viridian Therapeutics (Nasdaq: VRDN) announced a successful late‑October 2025 submission of a Biologics License Application (BLA) to the U.S. FDA for veligrotug, an IV anti‑IGF‑1R monoclonal antibody for thyroid eye disease (TED).
The BLA is supported by two pivotal phase 3 trials, THRIVE and THRIVE‑2, which met all primary and secondary endpoints and showed rapid clinical benefit, including statistically significant diplopia response and resolution. Veligrotug has Breakthrough Therapy designation and Viridian requested Priority Review; FDA will decide on BLA acceptance within 60 days.
Viridian Therapeutics (NASDAQ: VRDN) priced an underwritten public offering of 11,425,000 shares of common stock at $22.00 per share, with a 30-day underwriter option for an additional 1,713,750 shares. Gross proceeds are expected to be approximately $251,350,000 before underwriting discounts, commissions and offering expenses. The offering is expected to close on or about October 23, 2025. Viridian intends to use proceeds, together with existing cash and short-term investments, to fund commercial launch activities for veligrotug and VRDN-003, plus R&D, working capital and general corporate purposes.
Jefferies, Leerink Partners, Evercore ISI and Stifel are joint book-running managers; Wedbush PacGrow is co-manager. A registration statement became effective on September 5, 2025.
Viridian Therapeutics (NASDAQ: VRDN) announced on October 21, 2025 that it commenced an underwritten public offering of shares of common stock and Series B non-voting convertible preferred stock. The company said all offered securities will be sold by Viridian and the underwriters have a 30-day option to purchase additional common shares.
Each Series B share will be convertible into 66.67 shares of common stock, subject to beneficial ownership conversion limits. Viridian intends to use proceeds, together with cash and short-term investments, to fund commercial launch activities for veligrotug and VRDN-003, R&D, working capital and general corporate purposes. A registration statement became effective on September 5, 2025. Jefferies, Leerink Partners, Evercore ISI and Stifel are joint book-runners; Wedbush PacGrow is co-manager.
Viridian Therapeutics (NASDAQ: VRDN) entered a royalty financing and amended credit facility to raise up to $300 million. The company received a $55 million upfront payment and may receive up to $115 million in near-term milestones tied to positive VRDN-003 REVEAL topline data and U.S. veligrotug approval. Proceeds plus existing cash are expected to fully fund commercial launches of veligrotug and VRDN-003. Viridian expects to submit the veligrotug BLA imminently and now projects VRDN-003 topline readouts in REVEAL-1 Q1 2026 and REVEAL-2 Q2 2026. An amended Hercules credit facility provides up to $300 million, including a required $50 million draw at closing.
Viridian Therapeutics (Nasdaq: VRDN) announced on October 2, 2025 that its Compensation Committee approved inducement grants of non-qualified stock options to purchase an aggregate of 147,650 shares to 4 new employees, with a Grant Date of October 1, 2025. The options were granted outside the company's 2016 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Exercise price equals the closing price on the Grant Date. Vesting: 25% at one year, then monthly over 36 months, subject to continued employment.
Viridian Therapeutics (NASDAQ: VRDN) announced significant progress in its thyroid eye disease (TED) portfolio. The company has completed enrollment for both REVEAL-1 and REVEAL-2 phase 3 clinical trials for VRDN-003, exceeding target enrollment with 132 and 204 patients respectively. Topline data is expected in H1 2026.
Key developments include: USPTO granting composition patent for VRDN-003 until 2041, planned veligrotug BLA submission in November 2025 with potential mid-2026 launch under Priority Review, and positive VRDN-006 data showing consistent IgG reductions. The company's VRDN-008 IND submission remains on track for year-end 2025.